Pharmacokinetics of JS026 and JS026-JS016 for single intravenous administration in healthy volunteers
10.13699/j.cnki.1001-6821.2024.15.021
- VernacularTitle:JS026及JS026联合JS016注射液在健康受试者中的药代动力学研究
- Author:
Yan TIAN
1
;
Hui-Jing YE
;
Jing-Jing WANG
;
Nan-Yang LI
;
Juan MA
;
Xi TAN
;
Fan WU
;
Jie WANG
;
Shu-Yan YU
;
Xiao-Jie WU
;
Jin-Jie HE
;
Jing ZHANG
;
Wen-Hong ZHANG
Author Information
1. 复旦大学附属华山医院临床药理研究中心,上海 200040
- Keywords:
etesevimab;
JS026;
JS016;
tolerability;
safety;
pharmacokinetics
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(15):2251-2255
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate tolerability,safety and pharmacokinetics of JS026 and JS026-JS016 single dose intravenous infusion in healthy adults.Methods This phase 1,randomized,double-blind,placebo-controlled,dose-escalation study totally included 48 participants:32 healthy subjects were enrolled in JS026 single intravenous infusion groups and 16 healthy subjects were enrolled in JS026-JS016 groups.JS026 was sequentially administered from low dose to high dose(30-1 000 mg),with intravenous infusion of JS026 or placebo in JS026 single-dose groups,and intravenous infusion of JS026-JS016 or placebo in the combination drug groups.Blood was collected according to the time point designed for trial.Serum concentrations of JS026 and JS016 were determined by enzyme linked immunosorbnent assay(ELISA),and pharmacokinetics parameters were calculated by WinNonlin 8.2.The power model method was used to evaluate the linear analysis of dose and drug exposure.Results 47 subjects completed trial and 1 subject lost to follow-up.After a single intravenous injection of JS026 of 30 mg,100 mg,300 mg,600 mg,and 1 000 mg,mean Cmax were(9.47±1.53),(33.20±4.95),(96.10±13.70),(177.00±22.20)and(353.00±56.70)μg·mL-1,respectively;mean AUC0-∞ were(4 225.00±607.00),(1.78 × 104±3 268.00),(5.83 × 104±1 038.00),(1.07 × 105±152.00),(1.66 × 105±327.00)μg·h·mL-1,respectively;mean t1/2 of JS026 were 563-709 h.The Cmax and AUC0-∞ of JS026 were basically similar alone or in combination with JS016.The results of Power model showed that Cmax and AUC0-∞ increased approximately linearly with the increasing dose of JS026.Treatment emergent adverse event was not increasing when dose increased and most of adverse event associated with drugs were abnormal on laboratory tests and haematuria,thus JS026 and JS016 was well tolerated in all groups.Conclusion The single intravenous infusion of JS026 can almost be thought to be a linear relationship between the doses and drug serum exposure.JS016 had no significant effect on serum concentration of JS026 and JS026 was well tolerated and safe in healthy subjects within 30-1 000 mg.
